Anna Collen
Overview
Explore the profile of Anna Collen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sunnaker M, Bhattacharya C, Nelander K, Aurell M, Heijer M, Collen A, et al.
Clin Drug Investig
. 2024 Nov;
44(11):863-874.
PMID: 39495467
Background And Objective: Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease....
2.
Bhattacharya C, Pizzato P, Heijer M, Sunnaker M, Holden J, Trebski M, et al.
Br J Clin Pharmacol
. 2024 Aug;
90(12):3212-3220.
PMID: 39134325
Aims: Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio-metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics....
3.
Florida E, Li H, Hong C, Ongstad E, Gaddipati R, Sitaula S, et al.
J Am Heart Assoc
. 2023 Nov;
12(22):e031227.
PMID: 37982276
Background: Psoriasis is a chronic inflammatory condition associated with coronary artery disease risk. Uptake of oxidized low-density lipoprotein by the lectin-like low-density lipoprotein receptor-1 triggers release of the soluble extracellular...
4.
Sorokin A, Hong C, Aponte A, Florida E, Tang J, Patel N, et al.
JCI Insight
. 2023 Sep;
8(20.
PMID: 37698922
Background: Oxidized apolipoprotein B (oxLDL) and oxidized ApoA-I (oxHDL) are proatherogenic. Their prognostic value for assessing high-risk plaques by coronary computed tomography angiography (CCTA) is missing. Methods: In a prospective,...
5.
Lund L, Lam C, Pizzato P, Gabrielsen A, Michaelsson E, Nelander K, et al.
Eur J Heart Fail
. 2023 Jul;
25(9):1696-1707.
PMID: 37470101
Aims: Mitiperstat (formerly AZD4831) is a novel selective myeloperoxidase inhibitor. Currently, no effective therapies target comorbidity-induced systemic inflammation, which may be a key mechanism underlying heart failure with preserved or...
6.
Davidsson P, Eketjall S, Eriksson N, Walentinsson A, Becker R, Cavallin A, et al.
Cardiovasc Res
. 2023 Mar;
119(7):1596-1605.
PMID: 36869765
Aims: The vascular endothelial growth factor (VEGF) family is involved in pathophysiological mechanisms underlying cardiovascular (CV) diseases. The aim of this study was to investigate the associations between circulating VEGF...
7.
Vavere A, Sinsakul M, Ongstad E, Yang Y, Varma V, Jones C, et al.
J Am Heart Assoc
. 2023 Jan;
12(3):e027540.
PMID: 36688371
Background Blockade of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atherosclerosis. This study aims to assess...
8.
Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting
Anttila V, Saraste A, Knuuti J, Hedman M, Jaakkola P, Laugwitz K, et al.
Mol Ther
. 2022 Dec;
31(3):866-874.
PMID: 36528793
Vascular endothelial growth factor A (VEGF-A) has therapeutic cardiovascular effects, but delivery challenges have impeded clinical development. We report the first clinical study of naked mRNA encoding VEGF-A (AZD8601) injected ...
9.
Bost J, Ojansivu M, Munson M, Wesen E, Gallud A, Gupta D, et al.
Commun Biol
. 2022 Mar;
5(1):185.
PMID: 35233031
The therapeutic and research potentials of oligonucleotides (ONs) have been hampered in part by their inability to effectively escape endosomal compartments to reach their cytosolic and nuclear targets. Splice-switching ONs...
10.
Collen A, Bergenhem N, Carlsson L, Chien K, Hoge S, Gan L, et al.
Nat Rev Drug Discov
. 2021 Dec;
21(1):79-80.
PMID: 34873303
No abstract available.